Related Experiment Videos
Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Carmen Cerchia1, Antonio Lavecchia1
1Department of Pharmacy, "Drug Discovery" Laboratory, University of Napoli "Federico II", via D. Montesano 49, I-80131 Napoli, Italy.
Abstract:
Malignant melanoma is the most aggressive and life-threatening skin cancer. Melanoma develops in melanocytes and is characterized by a very high tendency to spread to other parts of the body. Its pathogenesis depends on DNA mutations leading to the activation of oncogenes or to the inactivation of suppressor genes. The identification of misregulations in intracellular signal transduction pathways has provided an opportunity for the development of mutation-specific inhibitors, which specifically target the mutated signaling cascades. Over the last few years, clinical trials with MAPK pathway inhibitors have shown significant clinical activity in melanoma; however, their efficacy is limited due to the onset of acquired resistance. This has prompted a large set of preclinical studies looking at new approaches of pathway- or target-specific inhibitors. This review gives an overview of the latest developments of small molecule targeting multiple molecular pathways in both preclinical and clinical melanoma settings, with particular emphasis on additional strategies to tackle the reduced responsiveness to inhibitor treatment as possible future directions.
Insights
Targeting molecular pathways in melanoma shows promise, but acquired resistance limits efficacy. New small molecule inhibitors and strategies are being developed to overcome resistance and improve melanoma treatment outcomes.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- Malignant melanoma is an aggressive skin cancer originating in melanocytes.
- Melanoma pathogenesis involves DNA mutations activating oncogenes or inactivating tumor suppressor genes.
- Intracellular signal transduction pathway misregulations offer therapeutic targets.
Purpose of the Study:
- To review recent advancements in small molecule inhibitors for melanoma.
- To highlight strategies for overcoming acquired resistance to targeted therapies.
- To discuss future directions in melanoma treatment.
Main Methods:
- Review of preclinical studies and clinical trials.
- Analysis of small molecule inhibitors targeting multiple molecular pathways.
- Investigation of resistance mechanisms and potential solutions.
Main Results:
- MAPK pathway inhibitors demonstrate clinical activity but face acquired resistance.
- Development of novel small molecule inhibitors targeting multiple pathways is ongoing.
- Emerging strategies aim to enhance responsiveness to inhibitor treatments.
Conclusions:
- Targeted therapies, particularly small molecule inhibitors, offer new avenues for melanoma treatment.
- Overcoming acquired resistance is crucial for improving long-term patient outcomes.
- Future research should focus on combination therapies and novel drug development.